Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Cyclic strain amplitude dictates the growth response of vascular smooth muscle cells in vitro: role in in-stent restenosis and inhibition with a sirolimus drug-eluting stent.

Colombo A, Guha S, Mackle JN, Cahill PA, Lally C.

Biomech Model Mechanobiol. 2013 Aug;12(4):671-83. doi: 10.1007/s10237-012-0433-4. Epub 2012 Sep 8.

PMID:
22961302
2.

Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model.

Yang W, Ge J, Liu H, Zhao K, Liu X, Qu X, Li W, Huang Y, Sun A, Zou Y.

Cardiovasc Res. 2006 Dec 1;72(3):483-93. Epub 2006 Aug 23.

PMID:
17020754
3.

Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells.

Clever YP, Cremers B, Krauss B, Böhm M, Speck U, Laufs U, Scheller B.

EuroIntervention. 2011 May;7 Suppl K:K32-42. doi: 10.4244/EIJV7SKA6.

PMID:
22027725
4.

Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents.

Chieffo A, Foglieni C, Nodari RL, Briguori C, Sangiorgi G, Latib A, Montorfano M, Airoldi F, Michev I, Carlino M, Colombo A, Maseri A.

Am J Cardiol. 2009 Dec 15;104(12):1660-7. doi: 10.1016/j.amjcard.2009.07.041.

PMID:
19962471
5.
6.

Comparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries.

Sheehy A, Hsu S, Bouchard A, Lema P, Savard C, Guy LG, Tai J, Polyakov I.

Cardiovasc Diabetol. 2012 Jun 21;11:75. doi: 10.1186/1475-2840-11-75.

7.

Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.

Wessely R, Blaich B, Belaiba RS, Merl S, Görlach A, Kastrati A, Schömig A.

Thromb Haemost. 2007 Jun;97(6):1003-12.

PMID:
17549304
8.
9.

Effect of a novel peptide, WKYMVm- and sirolimus-coated stent on re-endothelialization and anti-restenosis.

Jang EJ, Bae IH, Park DS, Lee SY, Lim KS, Park JK, Shim JW, Sim DS, Jeong MH.

J Mater Sci Mater Med. 2015 Oct;26(10):251. doi: 10.1007/s10856-015-5585-1. Epub 2015 Oct 5.

PMID:
26438653
10.

Two-dimensional fluorescence in-gel electrophoresis of coronary restenosis tissues in minipigs: increased adipocyte fatty acid binding protein induces reactive oxygen species-mediated growth and migration in smooth muscle cells.

Lu L, Wang YN, Sun WH, Liu ZH, Zhang Q, Pu LJ, Yang K, Wang LJ, Zhu ZB, Meng H, Yang P, Du R, Chen QJ, Wang LS, Yu H, Shen WF.

Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):572-80. doi: 10.1161/ATVBAHA.112.301016. Epub 2013 Jan 31.

11.

Molecular basis of different outcomes for drug-eluting stents that release sirolimus or tacrolimus.

Giordano A.

Curr Opin Drug Discov Devel. 2010 Mar;13(2):159-68. Review.

PMID:
20205050
12.

Smooth muscle-specific drug targets for next-generation drug-eluting stent.

Tang R, Chen SY.

Expert Rev Cardiovasc Ther. 2014 Jan;12(1):21-3. doi: 10.1586/14779072.2014.866518. Epub 2013 Dec 10. Review.

13.

Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells.

Matter CM, Rozenberg I, Jaschko A, Greutert H, Kurz DJ, Wnendt S, Kuttler B, Joch H, Grünenfelder J, Zünd G, Tanner FC, Lüscher TF.

J Cardiovasc Pharmacol. 2006 Dec;48(6):286-92.

PMID:
17204907
14.

Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation.

Torella D, Curcio A, Gasparri C, Galuppo V, De Serio D, Surace FC, Cavaliere AL, Leone A, Coppola C, Ellison GM, Indolfi C.

Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H2935-43. Epub 2007 Feb 9.

15.

Use of a novel anti-proliferative compound coated on a biopolymer to mitigate platelet-derived growth factor-induced proliferation in human aortic smooth muscle cells: comparison with sirolimus.

Tang YD, Pandey A, Kolmakova A, Wang XT, Venkatraman SS, Chatterjee S, Boey FY.

Glycoconj J. 2009 Aug;26(6):721-32. doi: 10.1007/s10719-008-9192-y. Epub 2008 Oct 14.

PMID:
18853254
17.

Comparison of long-term results of drug-eluting stent and bare metal stent implantation in heart transplant recipients with coronary artery disease.

Zakliczynski M, Lekston A, Osuch M, Swierad M, Nadziakiewicz P, Przybylski R, Zembala M.

Transplant Proc. 2007 Nov;39(9):2859-61.

PMID:
18022002
18.

Influence of Clinically Relevant Mechanical Forces on Vascular Smooth Muscle Cells Under Chronic High Glucose: An In Vitro Dynamic Disease Model.

Chawla V, Simionescu A, Langan EM 3rd, LaBerge M.

Ann Vasc Surg. 2016 Jul;34:212-26. doi: 10.1016/j.avsg.2016.04.003. Epub 2016 Apr 25.

PMID:
27126714
19.

Assessment of potential relationship between wall shear stress and arterial wall response after bare metal stent and sirolimus-eluting stent implantation in patients with diabetes mellitus.

Suzuki N, Nanda H, Angiolillo DJ, Bezerra H, Sabaté M, Jiménez-Quevedo P, Alfonso F, Macaya C, Bass TA, Ilegbusi OJ, Costa MA.

Int J Cardiovasc Imaging. 2008 Apr;24(4):357-64. Epub 2007 Oct 31.

PMID:
17972162
20.

A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan.

Segev A, Nili N, Osherov AB, Qiang B, Wong AJ, Pillarisetti S, Strauss BH.

EuroIntervention. 2010 May;6(1):134-40. doi: 10.4244/.

PMID:
20542809

Supplemental Content

Support Center